Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma.

Balasubramanian, Adithya; Gunjur, Ashray; Hafeez, Umbreen; Menon, Siddharth; Cher, Lawrence M; Parakh, Sagun; Gan, Hui Kong

Balasubramanian, Adithya; Gunjur, Ashray; Hafeez, Umbreen; Menon, Siddharth; Cher, Lawrence M; Parakh, Sagun; Gan, Hui Kong.

Afiliação

Balasubramanian A; Medical Oncology Department, Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Victoria, Australia.
Gunjur A; Medical Oncology Department, Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Victoria, Australia.
Hafeez U; Medical Oncology Department, Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Victoria, Australia.
Menon S; Olivia Newton-John Cancer Research Institute and La Trobe University School of Cancer Medicine, Heidelberg, Victoria, Australia.
Cher LM; Medical Oncology Department, Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Victoria, Australia.
Parakh S; Olivia Newton-John Cancer Research Institute and La Trobe University School of Cancer Medicine, Heidelberg, Victoria, Australia.
Gan HK; Medical Oncology Department, Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Victoria, Australia.

Neurooncol Adv ; 3(1): vdaa171, 2021.

Article em En | MEDLINE | ID: mdl-33543145

Palavras-chave

clinical trials; drug development; glioblastoma; glioma; phase II; phase III; trial design

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: Neurooncol Adv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Austrália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google